Sprouty2 Regulates Endocytosis and Degradation of Fibroblast Growth Factor Receptor 1 in Glioblastoma Cells
Cells · 2024
DOI: 10.3390/cells13231967 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Barbara Hausott und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Neuroanatomy, Medical University of Innsbruck, 6020 Innsbruck, Austria. Hauptthemen laut MEDLINE: Glioblastoma, Endocytosis, Receptor, Fibroblast Growth Factor, Type 1, Membrane Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FWF Austrian Science Fund, Austrian Science Fund (FWF).
Abstract (Originalsprache)
The Sprouty (SPRY) proteins are evolutionary conserved modulators of receptor tyrosine kinase (RTK) signaling. SPRY2 inhibits fibroblast growth factor (FGF) signaling, whereas it enhances epidermal growth factor (EGF) signaling through inhibition of EGF receptor (EGFR) endocytosis, ubiquitination, and degradation. In this study, we analyzed the effects of SPRY2 on endocytosis and degradation of FGF receptor 1 (FGFR1) using two human glioblastoma (GBM) cell lines with different endogenous SPRY2 levels. SPRY2 overexpression (SPRY2-OE) inhibited clathrin- and caveolae-mediated endocytosis of FGFR1, reduced the number of caveolin-1 vesicles and the uptake of transferrin. Furthermore, FGFR1 protein was decreased by SPRY2-OE, whereas EGFR protein was increased. SPRY2-OE enhanced FGFR1 degradation by increased c-casitas b-lineage lymphoma (c-CBL)-mediated ubiquitination, but it diminished binding of phospholipase Cγ1 (PLCγ1) to FGFR1. Consequently, SPRY2-OE inhibited FGF2-induced activation of PLCγ1, whereas it enhanced EGF-induced PLCγ1 activation. Despite the reduction of FGFR1 protein and the inhibition of FGF signaling, SPRY2-OE increased cell viability, and knockdown of SPRY2 enhanced the sensitivity to cisplatin. These results demonstrate that the inhibitory effect of SPRY2-OE on FGF signaling is at least in part due to the reduction in FGFR1 levels and the decreased binding of PLCγ1 to the receptor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Neuroanatomy, Medical University of Innsbruck, 6020 Innsbruck, Austria.
- Institute of Functional and Applied Anatomy, Hannover Medical School, 30625 Hannover, Germany.
- Center for Systems Neuroscience, 30625 Hannover, Germany.
- Department of Pediatrics II, Medical University of Innsbruck, 6020 Innsbruck, Austria.
ORCID-Profile: Barbara Hausott, Peter Claus, Lars Klimaschewski
Förderung
- FWF Austrian Science Fund
- Austrian Science Fund (FWF)
Zitieren
APA
Hausott, B., Pircher, L., Kind, M., Park, J. W., Claus, P., Obexer, P., & Klimaschewski, L. (2024). Sprouty2 Regulates Endocytosis and Degradation of Fibroblast Growth Factor Receptor 1 in Glioblastoma Cells. Cells. https://doi.org/10.3390/cells13231967
Vancouver
Hausott B, Pircher L, Kind M, Park JW, Claus P, Obexer P, et al. Sprouty2 Regulates Endocytosis and Degradation of Fibroblast Growth Factor Receptor 1 in Glioblastoma Cells. Cells. 2024. doi:10.3390/cells13231967
BibTeX
@article{Hausott2024,
author = {Hausott, Barbara and Pircher, Lena and Kind, Michaela and Park, Jong-Whi and Claus, Peter and Obexer, Petra and Klimaschewski, Lars},
title = {Sprouty2 Regulates Endocytosis and Degradation of Fibroblast Growth Factor Receptor 1 in Glioblastoma Cells},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13231967}
}
EUVIMED